TuHURA Biosciences, Inc. (HURA) 股票分析

公司概述

TuHURA Biosciences, Inc. operates as a clinical stage immuno-oncology company dedicated to developing novel technologies specifically for cancer immunotherapy treatments. Within the broader Healthcare sector and the specialized Biotechnology industry, the firm focuses on creating innovative therapeutic approaches to address oncological challenges. The company's current scale is defined by a market capitalization of $124.61M, while reported annual revenue figures are unavailable (N/A) for the trailing twelve months, and the organization employs a workforce of 22 individuals. This valuation and operational scope indicate that TuHURA is a small-cap entity with limited revenue history, positioning it as a high-risk, high-potential development-stage biotech firm that relies heavily on successful clinical outcomes rather than current cash flow generation to justify its market valuation.

财务健康

The company reports net income of $-30,060,332 over the trailing twelve months, with an EBITDA of $-28,045,056, while specific revenue data is not available, resulting in a gross margin of 0.0%, an operating margin of 0.0%, and a profit margin of 0.0%. The significant gap between the reported net income and EBITDA, alongside the zero margins, reveals a cost structure where operating expenses heavily outweigh any current revenue generation, a typical characteristic of early-stage drug development where R&D costs are capitalized or expensed before commercialization. Free cash flow stands at $-4,757,422, indicating that the company is currently burning cash to fund its operations and clinical trials, which severely limits its immediate financial flexibility and necessitates continuous capital raising. The balance sheet shows cash reserves of $3.62M against total debt of $700,022, resulting in a debt-to-equity ratio of 3.34, which suggests a highly leveraged capital structure relative to equity, though the absolute debt level is low compared to cash. A current ratio of 0.78 further highlights potential short-term liquidity constraints, as current liabilities exceed current assets, implying the company may struggle to meet obligations without external financing. Return on Equity is calculated at -169.2% and Return on Assets at -74.3%, metrics that reflect negative management effectiveness in generating shareholder value from current assets due to the inherent losses in the pre-commercialization phase.

估值评估

Valuation multiples for TuHURA present a complex picture, with a P/E Ratio (TTM) marked as N/A due to negative earnings, while the Forward P/E is listed at -3.38, implying that the market expects earnings to remain negative in the near future. The Price to Book ratio is 5.63, indicating that the stock trades at a significant premium relative to its tangible book value, a common phenomenon in biotech firms where market participants value future pipeline potential over current asset base. Alternative valuation metrics such as Price to Sales (N/A) and EV/EBITDA (-4.35) further underscore the lack of traditional profitability, with the negative EV/EBITDA reflecting the company's substantial cumulative losses and negative cash flow profile. The stock has experienced extreme volatility within the past year, with a 52-week high of $4.44 and a low of $0.41, suggesting the current price position is highly sensitive to clinical trial news and market sentiment rather than fundamental earnings growth. The Beta is listed as N/A, meaning that standard volatility relative to the broader market index cannot be quantified using available historical data, though the wide price range suggests high sensitivity to sector-specific movements.

Growth & Income

Revenue growth (YoY) and earnings growth (YoY) are both listed as N/A, preventing a direct comparison of growth rates between earnings and revenue due to the absence of comparable historical revenue data. As the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, confirming that TuHURA retains all available capital to reinvest into its research and development pipeline rather than distributing income to shareholders. This reinvestment strategy is standard for clinical stage biotechnology companies that prioritize accelerating clinical trials and expanding their product portfolio over providing immediate income returns to investors. Consequently, the overall growth and income profile of TuHURA is characterized by a complete reliance on capital appreciation and the potential for future commercialization of lead candidates like IFx2.0, rather than any current income generation or historical growth trajectory.